Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Fineline Cube Jul 28, 2026
Company Drug

Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials

Fineline Cube Jul 28, 2026
Company Drug

BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment

Fineline Cube Oct 20, 2023

The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...

Company Drug

CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment

Fineline Cube Oct 20, 2023

China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib...

Company

Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand

Fineline Cube Oct 20, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...

Company Drug

BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC

Fineline Cube Oct 20, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...

Company Deals

Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases

Fineline Cube Oct 20, 2023

Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...

Company Deals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

Fineline Cube Oct 20, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...

Company

HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy

Fineline Cube Oct 19, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...

Company

Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion

Fineline Cube Oct 19, 2023

Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...

Company Deals

Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics

Fineline Cube Oct 19, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...

Company Deals

Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China

Fineline Cube Oct 19, 2023

Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...

Company Drug

AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment

Fineline Cube Oct 19, 2023

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...

Legal / IP

CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Oct 19, 2023

The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...

Company Drug

Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023

Fineline Cube Oct 19, 2023

China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

Company R&D

WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain

Fineline Cube Oct 19, 2023

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...

Company Deals

AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development

Fineline Cube Oct 19, 2023

AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...

Company Drug

Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA

Fineline Cube Oct 19, 2023

Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...

Company Deals

Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services

Fineline Cube Oct 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...

Company Drug

Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management

Fineline Cube Oct 19, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Posts pagination

1 … 491 492 493 … 700

Recent updates

  • GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
  • AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds
  • Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend
  • Sanofi Halts Amlitelimab Development in Atopic Dermatitis Despite Positive Long-Term Safety Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Company Drug

Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials

Company

AstraZeneca Reports Solid Q2 2026 Results with 5% Revenue Growth Despite Farxiga Exclusivity Loss and China VBP Headwinds

Company Drug

Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.